Rapid Micro Biosystems
Rapid Micro Biosystems (Nasdaq: RPID) sells the Growth Direct automated rapid microbial detection platform and proprietary consumables to pharmaceutical and biotechnology manufacturers, replacing manual QC microbiology in environmental monitoring, bioburden, water, and sterility testing. The platform serves 75% of the top 20 global pharma companies and generates revenue from system placements plus recurring consumables and software.
- Company typePublic
- Founded2006
- HeadquartersBedford, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rapid Micro Biosystems does
Rapid Micro Biosystems (Nasdaq: RPID) is a Lexington, Massachusetts-based life sciences technology company that develops and sells the Growth Direct System, an automated rapid microbial detection platform for quality control microbiology in pharmaceutical and biotechnology manufacturing. The system combines LED-induced autofluorescence imaging with proprietary software algorithms to incubate, image, and count microbial colonies non-destructively, replacing manual plate-handling workflows for environmental monitoring, water testing, bioburden testing, and rapid sterility testing. Proprietary consumables — including media cassettes for TSA, R2A, and SDA formulations produced in cleanroom environments in Lowell, MA — generate recurring revenue tied to the installed base, while the RMBNucleus software platform (with Mold Alarm feature) provides instrument management, compliance reporting under 21 CFR Part 11, and bidirectional LIMS/MES integration.
The company operates a hybrid razor-and-blade business model: capital equipment placements of the Growth Direct system, complemented by high-margin recurring consumables, software subscriptions, and validation/support services. Sales are driven by an enterprise field-sales motion targeting pharmaceutical, biologics, sterile injectable, ATMP, and medical-device manufacturers, augmented by a strategic co-distribution partnership with MilliporeSigma (Merck KGaA) that entered its second year with a Q1 2026 Services Agreement. As of year-end 2025, the platform is used by 75% of the top 20 global pharmaceutical companies including Amgen, Biogen, Lonza, and Samsung Biologics.
FY2025 revenue was approximately $34M (up ~20% YoY), with Q4 2025 setting a record at $11.3M (+37% YoY) driven by a 16-system global rollout with Amgen. FY2026 guidance is $37-41M on expected 30-38 system placements. The company raised $45M in growth capital from Trinity Capital in September 2025 and completed an additional ~$9.8M underwritten offering in May 2026 (with up to ~$32M potential if warrants exercise), anchored by Bain Capital Life Sciences and Armistice Capital. Gross margins have lagged (trailing twelve months around 3%) due to under-absorbed manufacturing, but management is targeting mid-20% gross margins by year-end 2026 as production scales.
Rapid Micro Biosystems firmographics
Firmographics- Name
- Rapid Micro Biosystems
- Legal name
- Rapid Micro Biosystems, Inc.
- Website
- https://rapidmicrobio.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Rapid Micro Biosystems (Nasdaq: RPID) sells the Growth Direct automated rapid microbial detection platform and proprietary consumables to pharmaceutical and biotechnology manufacturers, replacing manual QC microbiology in environmental monitoring, bioburden, water, and sterility testing. The platform serves 75% of the top 20 global pharma companies and generates revenue from system placements plus recurring consumables and software.
- Ownership category
- akta.pro rank
Rapid Micro Biosystems industry classification
Industry- Product category
- Automated Microbial Quality Control Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where Rapid Micro Biosystems is headquartered
LocationHeadquarters
- HQ city
- Bedford
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
Rapid Micro Biosystems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Capital Equipment Sales: Sale of Growth Direct systems (capital equipment) to pharmaceutical and biotechnology manufacturers for automated microbial quality control testing. The company places systems through direct enterprise sales and strategic partnerships.
- Consumables and Test Kits: Recurring revenue from proprietary test consumables including environmental monitoring cassettes, bioburden cassettes, and sterility testing media. Stifel noted consumables growth exceeding 30% driven by expansion of the installed base.
- Software and Services: Recurring revenue from software licensing (RMBNucleus platform), support services, validation services, and application services. The company announced plans for cloud-native software platform launch in H2 2026.
- Validation and Support Services: Professional services including installation qualification, operational qualification, performance qualification, method qualification, and training. These services support customer implementation and ongoing system maintenance.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Rapid Micro Biosystems product offering
Product offeringCore offering
Rapid Micro Biosystems manufactures and sells the Growth Direct System, an automated rapid microbial detection platform that replaces slow, manual compendial quality control microbiology testing in pharmaceutical and biotechnology manufacturing. The platform combines proprietary autofluorescence imaging hardware, robotic plate handling, RMBNucleus data-management software, and single-use media cassettes to perform environmental monitoring, water testing, bioburden testing, and rapid sterility testing. Revenue is generated from capital equipment sales, recurring consumable cassettes, software licensing, and validation/support services.
Product overview
Rapid Micro Biosystems offers a unified platform architecture centered on the Growth Direct System, an automated rapid microbial detection platform that replaces slow, error-prone manual QC microbiology processes. The product portfolio includes the Growth Direct System hardware and software ecosystem, comprising RMBNucleus software (including the Mold Alarm feature) for instrument control, data management, and automated alerts. The platform is complemented by proprietary consumables including Environmental Monitoring cassettes (TSA-based), Bioburden cassettes (R2A, SDA, TSA), and Rapid Sterility Media. Service offerings include Validation Services, Support Services, and Application Services (feasibility studies and method development). The platform addresses four key QC testing applications: environmental monitoring, water testing, bioburden testing, and sterility testing, serving pharmaceutical, biotechnology, medical device, and personal care product manufacturers.
Differentiator
Problem solved
Functional benefit
Brands
- Growth Direct®: Flagship automated rapid microbial detection platform for pharmaceutical QC microbiology testing including environmental monitoring, water testing, bioburden testing, and sterility testing.
- RMBNucleus™
- RMBNucleus™ Mold Alarm
Products and services
- Growth Direct System Flagship automated rapid microbial detection platform that fully automates traditional compendial QC microbiology testing for environmental monitoring, bioburden testing, water testing, and rapid sterility testing. Targeted at pharmaceutical and biotechnology manufacturer QC labs.
- Growth Direct Rapid Sterility System Fully automated, non-destructive rapid sterility testing platform delivering time-to-detect in as little as 12 hours and final results in 1-3 days, processing up to 126 samples at once with closed-loop design to prevent contamination. For pharmaceutical QC sterility testing.
- Environmental Monitoring Consumable Cassettes Proprietary media-filled cassettes for environmental monitoring including TSA with Lecithin (ET80) and TSA with LP80HT, produced in controlled cleanroom environments and irradiated for high quality. For use with the Growth Direct System.
- Bioburden and Water Testing Consumable Cassettes Media cassettes for bioburden and water testing including R2A agar for water testing, Sabouraud Dextrose Agar (SDA) for yeasts and molds, and Tryptic Soy Agar (TSA) for general product testing, available in 48 cassettes per case.
- RMBNucleus Software Next-generation software platform for the Growth Direct System providing secure Windows 10 and SQL Server 2019 support, upgraded reporting and auditing compliant with 21 CFR Part 11, and streamlined recovery, monitoring, and user operation across multiple instruments.
- RMBNucleus Mold Alarm Automated mold detection software feature that triggers alerts when molds are detected during early stages of incubation, enabling investigations to begin in as little as one day and detecting molds commonly causing microbial contamination at temperatures up to 28°C.
- Validation Services Expert validation support partnering with pharmaceutical manufacturers for system qualification, including Installation Qualification (IQ), Operational Qualification (OQ), Performance Qualification (PQ), 21 CFR Part 11 Assessment, Method Qualification/Method Suitability (MQ/MS), and bi-directional LIMS integration, typically completed in four months.
- Support Services Comprehensive support including advanced remote monitoring, preventive maintenance, network connectivity for offsite operation, email alerts for Out Of Specification results and system issues, and an 18-hour-per-day support line.
- Application Services Feasibility studies and method development services performed in Lexington, MA and Freising, Germany laboratories, providing compatibility data, optimized methods, and documentation for Growth Direct System implementation, including product compatibility studies and recovery characteristics assessment.
Quantifiable outcome
- Time savings of up to 60% in bioburden detection (Biogen case study)
- +7 more outcomes
Companies that use Rapid Micro Biosystems
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Rapid Micro Biosystems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability2 records
Feature7 records
Rapid Micro Biosystems partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major and core.
- Samsung BiologicsmajorFollow-on multi-system order from Samsung Biologics to expand deployment of Growth Direct platform for automated microbial quality control. The order supports Samsung Biologics' continued expansion of the Growth Direct platform across its contract manufacturing operations, enhancing speed, accuracy, and data integrity in their manufacturing network.
- MilliporeSigma (Merck)coreStrategic partnership with MilliporeSigma (Merck) entered its second year with established demo labs. The partnership includes a Services Agreement executed in Q1 2026 to advance strategic collaboration. Expected to drive growth and improve gross margins starting in 2026. The company co-hosts Growth Direct Days events at Merck Innovation Center in Darmstadt, Germany.
- AmgenmajorRecord multi-system rollout from Amgen spanning North America, Europe, and Asia. This represents one of the largest deployments of the Growth Direct System with a top global pharmaceutical company, demonstrating regulatory acceptance and large-scale implementation capability.
Scale indicators14 records
Recent moves6 records
Expansion highlights6 records
Rapid Micro Biosystems competitors and assessment
Company assessmentDirect peers
- bioMérieux: Global leader in industrial and clinical microbiology, including automated microbial detection and identification platforms. Directly competes with Rapid Micro Biosystems in pharmaceutical QC microbial testing, particularly bioburden, sterility, and environmental monitoring workflows.
- Becton, Dickinson and Company (BD): Diversifies life sciences and diagnostics with the BD MAX and BD Phoenix M50 systems for microbial identification and detection, plus a broad consumables portfolio. Directly comparable in pharma QC microbiology automation and recurring consumables.
Broad incumbents
- Thermo Fisher Scientific: Operates a dedicated Microbiology Division offering culture media, identification, and detection systems used in pharma QC labs. RMB's CEO Robert Spignesi was previously VP/GM of Thermo Fisher's Microbiology Division, and Thermo is a broad incumbent with overlapping capabilities in lab analytical instruments.
- Charles River Laboratories: Major CRO/biopharma services provider that also runs QC microbiology testing and offers endotoxin/microbial detection products. Comparable as an incumbent operating across both lab services and consumables in pharmaceutical QC, including sterility and bioburden testing.
- Beckman Coulter (Danaher): Manufactures a wide range of clinical and life-science lab instruments, including microbiology automation, under Danaher's diagnostics platform. Comparable as a broad incumbent in laboratory analytical instruments with adjacency to pharma QC workflows.
Emerging players
- Sartorius AG: Supplies bioprocess and QC lab solutions to biopharma manufacturers, including microbial enumeration and contamination control offerings. Overlaps with RMB in biopharma QC lab automation, but is more anchored in upstream/downstream bioprocessing equipment.
- Hamilton Company: Specializes in automated liquid handling and lab robotics used in QC microbiology, genomics, and pharmaceutical workflows. Comparable as a provider of robotic lab automation that intersects with RMB's Growth Direct robotic imaging and plate handling.
Others
- Lonza Group: A leading global CDMO that is also a named RMB customer (Lonza deployed Growth Direct across its global network for end-to-end digital EM). Serves as a buyer and channel reference rather than a direct competitor, but their QC lab buying decisions shape demand for RMB's platform.
- Merck KGaA / MilliporeSigma: RMB's strategic distribution and demo-lab partner, with an existing Services Agreement to advance the collaboration. Offers competing microbiology QC products but is more directly relevant as the partner driving RMB's channel-led growth and co-hosted 'Growth Direct Days' events.
- Mettler-Toledo International: Manufactures precision laboratory instruments and process analytics used in pharmaceutical QC environments. Adjacent to RMB in lab analytical instrumentation serving regulated pharma manufacturing, though focused more on weighing, pH, and process analytics than microbial detection.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Rapid Micro Biosystems social profiles
Digital presenceRapid Micro Biosystems compliance and trust
Trust signalCompliance7 records
Rapid Micro Biosystems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rapid Micro Biosystems leadership team
Management profileNumber of profiles
Profiles9 records
Rapid Micro Biosystems funding detail
Funding detailFunding overview
Funding rounds14 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rapid Micro Biosystems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rapid Micro Biosystems
What does Rapid Micro Biosystems do?
Rapid Micro Biosystems manufactures and sells the Growth Direct System, an automated rapid microbial detection platform that replaces slow, manual compendial quality control microbiology testing in pharmaceutical and biotechnology manufacturing. The platform combines proprietary autofluorescence imaging hardware, robotic plate handling, RMBNucleus data-management software, and single-use media cassettes to perform environmental monitoring, water testing, bioburden testing, and rapid sterility testing. Revenue is generated from capital equipment sales, recurring consumable cassettes, software licensing, and validation/support services.
Is Rapid Micro Biosystems a public or private company?
Rapid Micro Biosystems is a public company. It is classified as public and is currently operating.
When was Rapid Micro Biosystems founded?
Rapid Micro Biosystems was founded in 2006. It employs 101 to 250 people.
Where is Rapid Micro Biosystems based?
Rapid Micro Biosystems is headquartered in Bedford, United States, in the North America region.
How does Rapid Micro Biosystems make money?
Four revenue lines are on record. Capital Equipment Sales are the primary driver. The others are consumables and Test Kits, software and Services and validation and Support Services.
Who are Rapid Micro Biosystems's main competitors?
Direct peers on record are bioMérieux and Becton, Dickinson and Company (BD). Broad incumbents are Thermo Fisher Scientific, Charles River Laboratories and Beckman Coulter (Danaher). Emerging players are Sartorius AG and Hamilton Company. Others are Lonza Group, Merck KGaA / MilliporeSigma and Mettler-Toledo International.
Does Rapid Micro Biosystems have an API?
No public API is recorded for Rapid Micro Biosystems.
What industry is Rapid Micro Biosystems in?
Rapid Micro Biosystems's product category is Automated Microbial Quality Control Instrumentation. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.